keyword
MENU ▼
Read by QxMD icon Read
search

etanercept serum

keyword
https://www.readbyqxmd.com/read/29340080/inhibition-of-tumor-necrosis-factor-signaling-attenuates-renal-immune-cell-infiltration-in-experimental-membranous-nephropathy
#1
Yen-Sung Huang, Shin-Huei Fu, Kuo-Cheng Lu, Jin-Shuen Chen, Hsin-Yi Hsieh, Huey-Kang Sytwu, Chia-Chao Wu
Idiopathic membranous nephropathy (MN) is an autoimmune-mediated glomerulonephritis and the most common cause of idiopathic nephrotic syndrome in adult humans. A tumor necrosis factor α (TNF-α)-mediated inflammatory response via TNF receptor 1 (TNFR1) and TNFR2 has been proposed as a pathogenic factor. In this study, we assessed the therapeutic response to blocking TNF signaling in experimental MN. Murine MN was induced experimentally by cationic bovine serum albumin (cBSA); phosphate-buffered saline was used in control mice...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29335345/s100a12-is-associated-with-response-to-therapy-in-juvenile-idiopathic-arthritis
#2
Faekah Gohar, Janneke Anink, Halima Moncrieffe, Lisette W A Van Suijlekom-Smit, Femke H M Prince, Marion A J van Rossum, Koert M Dolman, Esther P A H Hoppenreijs, Rebecca Ten Cate, Simona Ursu, Lucy R Wedderburn, Gerd Horneff, Michael Frosch, Dirk Foell, Dirk Holzinger
OBJECTIVE: Around one-third of patients with juvenile idiopathic arthritis (JIA) fail to respond to first-line methotrexate (MTX) or anti-tumor necrosis factor (TNF) therapy, with even fewer achieving ≥ American College of Rheumatology Pediatric 70% criteria for response (ACRpedi70), though individual responses cannot yet be accurately predicted. Because change in serum S100-protein myeloid-related protein complex 8/14 (MRP8/14) is associated with therapeutic response, we tested granulocyte-specific S100-protein S100A12 as a potential biomarker for treatment response...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29334162/prevalence-of-metabolic-syndrome-in-children-with-moderate-to-severe-psoriasis-treated-with-tnf-inhibitors-in-comparison-to-conventional-agents
#3
Nawaf Al Mutairi, Dhuha Alrqobah, Nasser Haji Hussain
Association of childhood psoriasis with metabolic syndrome has not been studied well. TNF-alfa contributes to the inflammation seen in metabolic syndrome, and recently etanercept has shown to reduce the levels of inflammatory markers. Assessment of prevalence of metabolic syndrome in juvenile psoriasis patients in Kuwait. We included 236 patients with moderate to severe psoriasis below 18 years treated for at least 24 weeks with TNF inhibitors (Group A), and equal number of age and sex matched cases treated with conventional medications (Group B)...
January 15, 2018: Dermatologic Therapy
https://www.readbyqxmd.com/read/29260891/tnf-%C3%AE-antagonism-with-etanercept-enhances-penile-nos-expression-cavernosal-reactivity-and-testosterone-levels-in-aged-rats
#4
Tuğçe Demirtaş Şahin, Yusufhan Yazir, Tijen Utkan, Gulcin Gacar, Selenay Furat Rençber, Semil Selcen Gocmez
Erectile dysfunction (ED) has been reported to be associated with inflammation. This study investigated the effects of tumor necrosis factor alpha (TNF-α) inhibitor etanercept on penile neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS) expressions, testosterone concentrations, neurogenic and endothelium-dependent relaxations of corpus cavernosum (CC), and circulating and cavernosal levels of inflammatory markers in aged rats. Animals were separated into control, aged, and etanercept-treated aged groups...
December 20, 2017: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/29232322/incidence-of-antidrug-antibodies-in-rheumatoid-arthritis-patients-from-argentina-treated-with-adalimumab-etanercept-or-infliximab-in-a-real-world-setting
#5
Pablo J Maid, Ricardo Xavier, Rosa M Real, Ron Pedersen, Qi Shen, Lisa Marshall, Gaston Solano, Cecilia Elena Borlenghi, Rodolfo Pardo Hidalgo
BACKGROUND: Biologic agents may induce immune responses that could impact drug action. OBJECTIVES: The aims of this study were to assess antidrug antibodies (ADAs) in patients with rheumatoid arthritis (RA) from Argentina treated with etanercept, adalimumab, or infliximab at a single visit and correlate it with efficacy outcomes. METHODS: In this subset analysis of a noninterventional, multinational, cross-sectional study (NCT01981473), adult patients with RA treated continuously for 6 to 24 months with etanercept, adalimumab, or infliximab were evaluated for ADAs and trough drug concentrations of 2 days or less prior to the next scheduled dose...
December 12, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29185966/the-prevalence-and-clinical-effect-of-immunogenicity-of-tnf-%C3%AE-blockers-in-patients-with-axial-spondyloarthritis
#6
Gil Bornstein, Merav Lidar, Pnina Langevitz, Alexander Fardman, Ilan Ben-Zvi, Chagai Grossman
OBJECTIVES: To evaluate the prevalence of immunogenicity of TNF-α blockers in axial spondyloarthritis (SpA) patients and to assess the effect of immunogenicity on drug levels and clinical response. METHPDS: Patients with axial SpA treated with either infliximab (INF), adalimumab (ADA) or etanercept (ETN) were recruited to our observational cross-sectional study. Demographic and clinical data were collected and disease activity scores were assessed. Drug trough levels and anti-drug antibodies were measured in serum samples and collected before the next administration...
November 28, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29142035/the-sex-influence-on-response-to-tumor-necrosis-factor-%C3%AE-inhibitors-and-remission-in-axial-spondyloarthritis
#7
Ennio Lubrano, Fabio Massimo Perrotta, Maria Manara, Salvatore D'Angelo, Olga Addimanda, Roberta Ramonda, Leonardo Punzi, Ignazio Olivieri, Carlo Salvarani, Antonio Marchesoni
OBJECTIVE: The aim of this study was to evaluate the influence of sex on response to treatment and disease remission in patients with axial spondyloarthritis (axSpA). METHODS: In this retrospective multicenter study, patients with axSpA, according to the Assessment of Spondyloarthritis international Society (ASAS) criteria for axSpA, and treated with adalimumab, etanercept, golimumab, or infliximab, were studied. We compared clinical characteristics, patient-reported outcomes, disease activity, function, and response to treatment in male and female patients with this disease...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29130929/tnf-regulates-transcription-of-nlrp3-inflammasome-components-and-inflammatory-molecules-in-cryopyrinopathies
#8
Matthew D McGeough, Alexander Wree, Maria E Inzaugarat, Ariela Haimovich, Casey D Johnson, Carla A Peña, Raphaela Goldbach-Mansky, Lori Broderick, Ariel E Feldstein, Hal M Hoffman
The NLRP3 inflammasome is a protein complex responsible for caspase-1-dependent maturation of the proinflammatory cytokines IL-1β and IL-18. Gain-of-function missense mutations in NLRP3 cause the disease spectrum known as the cryopyrin-associated periodic syndromes (CAPS). In this study, we generated Nlrp3-knockin mice on various KO backgrounds including Il1b/Il18-, caspase-1-, caspase-11- (Casp1/11-), and Tnf-deficient strains. The Nlrp3L351P Il1b-/- Il18-/- mutant mice survived and grew normally until adulthood and, at 6 months of age, exhibited marked splenomegaly and leukophilia...
November 13, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29106714/pharmacokinetics-immunogenicity-and-efficacy-of-etanercept-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis
#9
Richard G Langley, Sree Kasichayanula, Mona Trivedi, Girish A Aras, Arunan Kaliyaperumal, Theresa Yuraszeck, John Gibbs, Megan Gibbs, Greg Kricorian, Amy S Paller
Etanercept has been recently approved in the United States for the treatment of moderate to severe plaque psoriasis in patients aged 4-17 years. The objective of this study was to characterize etanercept pharmacokinetics, immunogenicity, and efficacy in pediatric patients. Data from a phase 3 study and open-label extension study were analyzed. Etanercept serum concentrations in pediatric patients receiving etanercept 0.8 mg/kg (maximum, 50 mg) weekly were compared with adult psoriasis patients and pediatric patients with juvenile idiopathic arthritis (JIA) who received etanercept 0...
November 6, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29104875/a-novel-system-for-the-quantification-of-the-adcc-activity-of-therapeutic-antibodies
#10
Christophe Lallemand, Feifei Liang, Flore Staub, Maud Simansour, Benoit Vallette, Lue Huang, Rosa Ferrando-Miguel, Michael G Tovey
Novel ADCC effector cells expressing the V-variant or F-variant of FcγRIIIa (CD16a) and firefly luciferase under the control of a chimeric promoter incorporating recognition sequences for the principal transcription factors involved in FcγRIIIa signal transduction, together with novel target cells overexpressing a constant high level of the specific antigen recognized by rituximab, trastuzumab, cetuximab, infliximab, adalimumab, or etanercept, confer improved sensitivity, specificity, and dynamic range in an ADCC assay relative to effector cells expressing a NFAT-regulated reporter gene and wild-type target cells...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/29067845/serum-interleukin-6-and-survivin-levels-predict-clinical-response-to-etanercept-treatment-in-patients-with-established-rheumatoid-arthritis-methodological-issues
#11
Erfan Ayubi, Saeid Safiri
No abstract text is available yet for this article.
October 25, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29063487/targeting-of-circulating-th17-cells-by-%C3%AE-d-mannuronic-acid-m2000-as-a-novel-medication-in-patients-with-rheumatoid-arthritis
#12
Hossein Ahmadi, Mahdi Mahmoudi, Farhad Gharibdoost, Mahdi Vojdanian, Ahmad Reza Jamshidi, Mohammad Javad Fattahi, Zahra Aghazadeh, Anis Barati, Abbas Mirshafiey
OBJECTIVE: This study aimed at investigating the inhibitory effect of β-D-mannuronic acid (M2000) on the Th17 circulating levels and IL-17 a related cytokine in rheumatoid arthritis (RA) patients. METHODS: The study included 27 patients with RA who had failed response to treatment. All patients were treated orally by M2000 at a dose of 500 mg twice daily for 12 weeks (Clinical trial identifier: IRCT2014011213739N2). The patients based on anti-tumor necrosis factor alpha (TNFα) blocker treatment were classified into two groups (conventional group and etanercept group)...
October 23, 2017: Inflammopharmacology
https://www.readbyqxmd.com/read/29026983/quartz-crystal-microbalance-as-an-assay-to-detect-anti-drug-antibodies-for-the-immunogenicity-assessment-of-therapeutic-biologics
#13
Evan A Dubiel, Tamás Fülöp, Sylvain Vigier, Patrick Vermette
Because of their biological origins, therapeutic biologics can trigger an unwanted deleterious immune response with some patients. The immunogenicity of therapeutic biologics can affect drug efficacy and patient safety by the production of circulating anti-drug antibodies (ADA). In this study, quartz crystal microbalance (QCM) was developed as an assay to detect ADA. Etanercept (Enbrel®) was covalently grafted to dextran-modified QCM surfaces. Rabbits were immunized with etanercept to generate ADA. Results showed the QCM assay could detect purified ADA from rabbits at concentrations as low as 50 ng/mL, within the sensitivity range of ELISA...
October 12, 2017: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/28903122/impact-of-ixekizumab-treatment-on-depressive-symptoms-and-systemic-inflammation-in-patients-with-moderate-to-severe-psoriasis-an-integrated-analysis-of-three-phase-3-clinical-studies
#14
Christopher E M Griffiths, Maurizio Fava, Andrew H Miller, James Russell, Susan G Ball, Wen Xu, Nayan Acharya, Mark Hyman Rapaport
BACKGROUND: Depression is a common comorbidity in psoriasis, and both conditions are associated with systemic inflammation. The efficacy of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, was evaluated in patients with moderate-to-severe plaque psoriasis (psoriasis) and depressive symptoms that were at least moderately severe. METHODS: Data were integrated from 3 randomized, double-blind, controlled phase 3 trials. At baseline and week 12, depressive symptoms and inflammation were assessed by the 16-item Quick Inventory of Depressive Symptomology - Self-Report (QIDS-SR16) and by a high-sensitivity assay of serum C-reactive protein (hsCRP), respectively...
2017: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/28822031/advances-in-the-management-of-thyroid-eye-diseases-an-overview
#15
REVIEW
Rashmi Kumari, Bhawesh Chandra Saha
INTRODUCTION: Thyroid eye disease (TED) remains a notorious ailment for both patients and the treating ophthalmologists. Recent years have witnessed considerable research in the immunopathogenic mechanism of TED that has resulted in an expansion and modification of the available management options. AIM: Purpose of this review is to summarise the advances in the management of thyroid ophthalmopathy. MATERIAL AND METHOD: A thorough literature search and of the past 10 years web search with words Thyroid ophthalmopathy, recent, advances...
August 18, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28700530/retrospective-study-of-patients-on-etanercept-therapy-for-rheumatic-diseases-in-patients-with-chronic-hepatitis-c-virus
#16
Nisarg P Gandhi, Augustine M Manadan, Joel A Block
OBJECTIVE: Treatment of rheumatic diseases with concurrent hepatitis C virus (HCV) infection is a therapeutic challenge. Etanercept has no known hepatotoxicity; however there is a concern for worsening of HCV infection-related liver disease due to immunosuppressive action of the drug. Here, we retrospectively assessed the safety of etanercept in rheumatologic disease in patients with chronic HCV. METHODS: A retrospective review was conducted in patients with chronic HCV infection who received etanercept for diagnosis of rheumatoid arthritis and psoriatic arthritis...
August 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28691952/intrapatient-variability-in-the-pharmacokinetics-of-etanercept-maintenance-treatment
#17
Ji S van Bezooijen, Marco W J Schreurs, Birgit C P Koch, Henk Te Velthuis, Martijn B A van Doorn, Errol P Prens, Teun van Gelder
AIM: Etanercept has shown to mediate a favorable effect on immune-mediated inflammatory diseases (IMID), including plaque psoriasis. Therapeutic drug monitoring (TDM) of etanercept could improve clinical outcome and cost-effectiveness. A high intrapatient variability (IPV) of etanercept trough concentrations at standard dosing would reduce the feasibility of therapeutic drug monitoring. Studies have focused on the interpatient differences associated with the exposure to biologics. The aim of this study was to determine IPV of etanercept and correlate etanercept trough concentrations and IPV with treatment response...
August 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28657833/serum-interleukin-6-and-survivin-levels-predict-clinical-response-to-etanercept-treatment-in-patients-with-established-rheumatoid-arthritis
#18
Rui Shi, Muzhi Chen, Bahaerguli Litifu
OBJECTIVES: To investigate the correlation of nine potential biomarkers with clinical response to etanercept (ETN) therapy in establish rheumatoid arthritis (RA) patients. METHODS: Seventy-three patients with established RA were enrolled in the prospective cohort study. Sixty-nine of 73 cases were included into final analysis for response after 24-week ETN therapy. Serum expression of nine studied proteins was measured by enzyme-linked immunosorbent assay (ELISA)...
June 28, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28657729/a-generic-hplc-method-for-absolute-quantification-of-oxidation-in-monoclonal-antibodies-and-fc-fusion-proteins-using-uv-and-ms-detection
#19
Christof Regl, Therese Wohlschlager, Johann Holzmann, Christian G Huber
Oxidation of biopharmaceuticals may affect their bioactivity, serum half-life, and (bio)chemical stability. The Fc domain of IgG monoclonal antibodies (mAbs) contains two methionine residues which are susceptible to oxidation. Here, we present a middle-down approach employing the cysteine protease IdeS under reducing conditions to obtain three mAb subunits of approximately 25 kDa: Fc/2, Fd', and LC. These subunits were separated by ion-pair reversed-phase high-performance liquid chromatography (IP-RP-HPLC) and detected by UV spectroscopy as well as Orbitrap mass spectrometry (MS), as well as MS upon all-ion fragmentation (AIF-MS)...
July 25, 2017: Analytical Chemistry
https://www.readbyqxmd.com/read/28638112/the-structure-function-relationship-of-disulfide-bonds-in-etanercept
#20
William C Lamanna, Robert Ernst Mayer, Alfred Rupprechter, Michael Fuchs, Fabian Higel, Cornelius Fritsch, Cornelia Vogelsang, Andreas Seidl, Hansjoerg Toll, Martin Schiestl, Johann Holzmann
Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis. Physicochemical and functional investigation of process fractions during development of the etanercept biosimilar GP2015 (Erelzi(®)) revealed a correlation between reduced potency and incorrect disulfide bridging between specific cysteines in the receptor domain. This novel structure-function relationship was found to be the molecular basis for reduced potency in recent Enbrel(®) batches, which exhibit higher levels of incorrect disulfide bridging...
June 21, 2017: Scientific Reports
keyword
keyword
40652
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"